| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
FDA
|
Unknown |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | FDA public meeting to gather stakeholder input on CBD products. | Unknown | View |
This document is a market research report from Cowen Washington Research Group dated February 25, 2019, authored by Assaraf and watermarked for Michael Cella. It analyzes the regulatory landscape for CBD following the passage of the 2018 Farm Bill, specifically highlighting that while hemp was declassified, the FDA (under Commissioner Scott Gottlieb) retains authority over CBD products making health claims or used in food. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a Congressional investigation.
This Cowen report page discusses the global regulatory landscape for CBD, highlighting developments in Europe and Latin America, and analyzes the U.S. regulatory outlook following the 2018 Farm Bill. It details the shifting oversight from the DEA to the Department of Agriculture while noting continued FDA authority and regulatory uncertainty regarding CBD products.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity